The long range objective of the proposed work is to relate the potent biological effects of the antitumor antibiotic CC-1065 to the structural modification of DNA which occurs upon covalent binding. CC-1065 is a potent antitumor agent produced by Streptomyces zelensis which was isolated by scientists at the Upjohn Company. Although the lead compound CC-1065 is too toxic for clinical use as an antitumor agent, a synthetic analog has been prepared which has improved antitumor efficacy in mice, and lacks the delayed death effects produced by CC-1065. During the next grant period we will continue studies in two areas; correlation of DNA binding and sequence specificity with biochemical and biological consequences, and structural investigations on the CC-1065-DNA adducts. In addition, we will initiate two new research areas: effect of CC-1065 binding to DNA on DNA protein recognition and function, and isolation and identification of proteins which bind specifically to DNA sequences modified with CC-1065. Correlation of DNA binding with biological effects will rely upon DNA sequencing techniques, and determination of cytotoxicity, antitumor efficacy and delayed death. Structural studies will utilize high-field NMR and gel electrophoresis. The effect on transcription factor binding and function will be assayed using immunoprecipitation, DNA footprinting techniques, and microinjections into frog oocyte cells. Proteins that bind to CC-1065-DNA adducts will be isolated by affinity techniques and identified by microsequencing and gene cloning.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA030349-08
Application #
3169226
Study Section
Chemical Pathology Study Section (CPA)
Project Start
1981-07-01
Project End
1989-11-30
Budget Start
1988-12-01
Budget End
1989-11-30
Support Year
8
Fiscal Year
1989
Total Cost
Indirect Cost
Name
University of Texas Austin
Department
Type
Schools of Pharmacy
DUNS #
City
Austin
State
TX
Country
United States
Zip Code
78713
Chapman, P B; Houghton, A N (1991) Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody. J Clin Invest 88:186-92
Hurley, L H (1989) DNA and associated targets for drug design. J Med Chem 32:2027-33
Hurley, L H; Boyd, F L (1988) DNA as a target for drug action. Trends Pharmacol Sci 9:402-7
Hurley, L H; Lee, C S; McGovren, J P et al. (1988) Reaction of CC-1065 and select synthetic analogs with DNA. Biochem Pharmacol 37:1795-6
Warpehoski, M A; Hurley, L H (1988) Sequence selectivity of DNA covalent modification. Chem Res Toxicol 1:315-33
Hurley, L H; Lee, C S; McGovren, J P et al. (1988) Molecular basis for sequence-specific DNA alkylation by CC-1065. Biochemistry 27:3886-92
Tang, M S; Lee, C S; Doisy, R et al. (1988) Recognition and repair of the CC-1065-(N3-adenine)-DNA adduct by the UVRABC nucleases. Biochemistry 27:893-901
Hurley, L H; Needham-VanDevanter, D R; Lee, C S (1987) Demonstration of the asymmetric effect of CC-1065 on local DNA structure using a site-directed adduct in a 117-base-pair fragment from M13mp1. Proc Natl Acad Sci U S A 84:6412-6
Reynolds, V L; McGovren, J P; Hurley, L H (1986) The chemistry, mechanism of action and biological properties of CC-1065, a potent antitumor antibiotic. J Antibiot (Tokyo) 39:319-34
Needham-VanDevanter, D R; Hurley, L H (1986) Construction and characterization of a site-directed CC-1065-N3-adenine adduct within a 117 base pair DNA restriction fragment. Biochemistry 25:8430-6

Showing the most recent 10 out of 13 publications